Effects of microRNA‑20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN/PI3K/AKT signaling pathway

Jiang,Yanxia; Chang,Hong; Chen,Guoan

doi:10.3892/ol.2018.8555

Effects of microRNA‑20a on the proliferation, migration and apoptosis of multiple myeloma via the PTEN/PI3K/AKT signaling pathway

Authors:
- Yanxia Jiang
- Hong Chang
- Guoan Chen
View Affiliations

Affiliations: Department of Hematology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China, Division of Molecular and Cellular Biology, Toronto General Research Institute, Toronto, ON M5G 2C4, Canada
Published online on: April 23, 2018 https://doi.org/10.3892/ol.2018.8555
Pages: 10001-10007

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple myeloma (MM) is a heterogeneous disease with a poor prognosis. Circulating microRNAs (miRNAs) have shown potential as non‑invasive prognostic biomarkers for heterogeneous diseases. miR‑20a has been shown involved in various human cancers, and the phosphatase and tensin homolog/phosphoinositide 3‑kinase/protein kinase B (PTEN/P13K/Akt) signaling pathway plays a key role in cell proliferation, migration and apoptosis. Here, we investigated the effect of miR‑20a on the PTEN/PI3K/Akt signaling pathway during MM cell proliferation, migration and apoptosis. Reverse transcription quantitative polymerase chain reaction was applied to detect miR‑20a expression in plasma from 30 MM patients and MM cell lines. CCK-8 assays, Transwell assays, Annexin V/PI double‑staining and western blotting were performed to examine the protein expressions of PTEN, PI3K and Akt during cellullar proliferation, migration, cycling, and apoptosis. Significant upregulation of miR‑20a and deregulation of PTEN were observed in MM cells. We also identified PTEN as a downstream target gene of miR‑20a, which bound to the 3'-untranslated region of PTEN. Overexpression of miR‑20a was associated with decreased PTEN expression, and treatment with miR‑20a inhibitors decreased cell proliferation, migration and clonogenicity and reduced the protein expressions of PI3K and p‑Akt but increased PTEN protein expression compared with blank and negative control groups. Taken together, these results showed that inhibition of miR‑20a suppresses MM progression by modulating the PTEN/PI3K/Akt signaling pathway. These findings suggest that miR‑20a may be a novel molecular therapeutic target for the treatment of MM.

View Figures

View References

1	Sonneveld P, Avet-Loiseau H, Lonial S, Usmani S, Siegel D, Anderson KC, Chng WJ, Moreau P, Attal M, Kyle RA, et al: Treatment of multiple myeloma with high-risk cytogenetics: A consensus of the international myeloma working group. Blood. 127:2955–2962. 2016. View Article : Google Scholar : PubMed/NCBI
2	Abdi J, Chen G and Chang H: Erratum: Drug resistance in multiple myeloma: Latest findings and new concepts on molecular mechanisms. Oncotarget. 6:73642015.PubMed/NCBI
3	Mimura N, Hideshima T and Anderson KC: Novel therapeutic strategies for multiple myeloma. Exp Hematol. 43:732–741. 2015. View Article : Google Scholar : PubMed/NCBI
4	Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, Haessler J, Feather J, Hoering A, Moreau P, et al: Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study. Leukemia. 26:149–157. 2012. View Article : Google Scholar : PubMed/NCBI
5	Lionetti M, Biasiolo M, Agnelli L, Todoerti K, Mosca L, Fabris S, Sales G, Deliliers GL, Bicciato S, Lombardi L, et al: Identification of microRNA expression patterns and definition of a microRNA/mRNA regulatory network in distinct molecular groups of multiple myeloma. Blood. 114:e20–e26. 2009. View Article : Google Scholar : PubMed/NCBI
6	Calin GA and Croce CM: MicroRNAs and chromosomal abnormalities in cancer cells. Oncogene. 25:6202–6210. 2006. View Article : Google Scholar : PubMed/NCBI
7	Calin GA and Croce CM: MicroRNA-cancer connection: The beginning of a new tale. Cancer Res. 66:7390–7394. 2006. View Article : Google Scholar : PubMed/NCBI
8	Luo X, Gu J, Zhu R, Feng M, Zhu X, Li Y and Fei J: Integrative analysis of differential miRNA and functional study of miR-21 by seed-targeting inhibition in multiple myeloma cells in response to berberine. BMC Syst Biol. 8:822014. View Article : Google Scholar : PubMed/NCBI
9	Seckinger A, Meißner T, Moreaux J, Benes V, Hillengass J, Castoldi M, Zimmermann J, Ho AD, Jauch A, Goldschmidt H, et al: miRNAs in multiple myeloma-a survival relevant complex regulator of gene expression. Oncotarget. 6:39165–39183. 2015. View Article : Google Scholar : PubMed/NCBI
10	Leotta M, Biamonte L, Raimondi L, Ronchetti D, Di Martino MT, Botta C, Leone E, Pitari MR, Neri A, Giordano A, et al: A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells. J Cell Physiol. 229:2106–2116. 2014. View Article : Google Scholar : PubMed/NCBI
11	Chi J, Ballabio E, Chen XH, Kušec R, Taylor S, Hay D, Tramonti D, Saunders NJ, Littlewood T, Pezzella F, et al: MicroRNA expression in multiple myeloma is associated with genetic subtype, isotype and survival. Biol Direct. 6:232011. View Article : Google Scholar : PubMed/NCBI
12	Esquela-Kerscher A: The lin-4 microRNA: The ultimate micromanager. Cell Cycle. 13:1060–1061. 2014. View Article : Google Scholar : PubMed/NCBI
13	Iorio MV and Croce CM: microRNA involvement in human cancer. Carcinogenesis. 33:1126–1133. 2012. View Article : Google Scholar : PubMed/NCBI
14	Garzon R and Marcucci G: Potential of microRNAs for cancer diagnostics, prognostication and therapy. Curr Opin Oncol. 24:655–659. 2012. View Article : Google Scholar : PubMed/NCBI
15	Yang R, Fu Y, Zeng Y, Xiang M, Yin Y, Li L, Xu H, Zhong J and Zeng X: Serum miR-20a is a promising biomarker for gastric cancer. Biomed Rep. 6:429–434. 2017. View Article : Google Scholar : PubMed/NCBI
16	Huang G, Chen X, Cai Y, Wang X and Xing C: miR-20a-directed regulation of BID is associated with the TRAIL sensitivity in colorectal cancer. Oncol Rep. 37:571–578. 2017. View Article : Google Scholar : PubMed/NCBI
17	Zhang H, Mao F, Shen T, Luo Q, Ding Z, Qian L and Huang J: Plasma miR-145, miR-20a, miR-21 and miR-223 as novel biomarkers for screening early-stage non-small cell lung cancer. Oncol Lett. 13:669–676. 2017. View Article : Google Scholar : PubMed/NCBI
18	Xiong Y, Sun F, Dong P, Watari H, Yue J, Yu MF, Lan CY, Wang Y and Ma ZB: iASPP induces EMT and cisplatin resistance in human cervical cancer through miR-20a-FBXL5/BTG3 signaling. J Exp Clin Cancer Res. 36:482017. View Article : Google Scholar : PubMed/NCBI
19	Peng J, Thakur A, Zhang S, Dong Y, Wang X, Yuan R, Zhang K and Guo X: Expressions of miR-181a and miR-20a in RPMI8226 cell line and their potential as biomarkers for multiple myeloma. Tumour Biol. 36:8545–8552. 2015. View Article : Google Scholar : PubMed/NCBI
20	Wang W, Corrigan-Cummins M, Barber EA, Saleh LM, Zingone A, Ghafoor A, Costello R, Zhang Y, Kurlander RJ, Korde N, et al: Aberrant levels of miRNAs in bone marrow microenvironment and peripheral blood of myeloma patients and disease progression. J Mol Diagn. 17:669–678. 2015. View Article : Google Scholar : PubMed/NCBI
21	Luo M, Tan X, Mu L, Luo Y, Li R, Deng X, Chen N, Ren M, Li Y, Wang L, et al: MiRNA-21 mediates the antiangiogenic activity of metformin through targeting PTEN and SMAD7 expression and PI3K/AKT pathway. Sci Rep. 7:434272017. View Article : Google Scholar : PubMed/NCBI
22	Liu MH, Yang L, Liu XJ, Nie ZY and Luo JM: Targeted suppression of miRNA-21 inhibit K562 cells growth through PTEN-PI3K/AKT signaling pathway. Zhonghua Xue Ye Xue Za Zhi. 37:982–986. 2016.(In Chinese). PubMed/NCBI
23	Yang X, Cheng Y, Li P, Tao J, Deng X, Zhang X, Gu M, Lu Q and Yin C: A lentiviral sponge for miRNA-21 diminishes aerobic glycolysis in bladder cancer T24 cells via the PTEN/PI3K/AKT/mTOR axis. Tumour Biol. 36:383–91. 2015. View Article : Google Scholar : PubMed/NCBI
24	Wang F, Li L, Chen Z, Zhu M and Gu Y: MicroRNA-214 acts as a potential oncogene in breast cancer by targeting the PTEN-PI3K/Akt signaling pathway. Int J Mol Med. 37:1421–1428. 2016. View Article : Google Scholar : PubMed/NCBI
25	Anderson KC: Progress and paradigms in multiple myeloma. Clin Cancer Res. 22:5419–5427. 2016. View Article : Google Scholar : PubMed/NCBI
26	Yang Z, Fang S, Di Y, Ying W, Tan Y and Gu W: Modulation of NF-κB/miR-21/PTEN pathway sensitizes non-small cell lung cancer to cisplatin. PLoS One. 10:e01215472015. View Article : Google Scholar : PubMed/NCBI
27	Zhang Y, Zheng L, Ding Y, Li Q, Wang R, Liu T, Sun Q, Yang H, Peng S, Wang W and Chen L: MiR-20a induces cell radioresistance by activating the PTEN/PI3K/Akt signaling pathway in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 92:1132–1140. 2015. View Article : Google Scholar : PubMed/NCBI
28	Bates SE: Multiple myeloma: Multiplying therapies. Clin Cancer Res. 22:54182016. View Article : Google Scholar : PubMed/NCBI
29	Wang X, Zhang H, Zhang A, Han L, Wang K, Liu R, Yang S, Pu P, Shen C, Kang O and Yu C: Upregulation of miR-20a and miR-106b is involved in the acquisition of malignancy of pediatric brainstem gliomas. Oncol Rep. 28:1293–1300. 2012. View Article : Google Scholar : PubMed/NCBI
30	Li S, Qiang Q, Shan H, Shi M, Gan G, Ma F and Chen B: miR-20a and miR-20b negatively regulate autophagy by targeting RB1CC1/FIP200 in breast cancer cells. Life Sci. 147:143–152. 2016. View Article : Google Scholar : PubMed/NCBI
31	Gao X, Zhang R, Qu X, Zhao M, Zhang S, Wu H, Jianyong L and Chen L: MiR-15a, miR-16-1 and miR-17-92 cluster expression are linked to poor prognosis in multiple myeloma. Leuk Res. 36:1505–1509. 2012. View Article : Google Scholar : PubMed/NCBI
32	Medema RH, Kops GJ, Bos JL and Burgering BM: AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature. 404:782–787. 2000. View Article : Google Scholar : PubMed/NCBI
33	Roy SK, Srivastava RK and Shankar S: Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal. 5:102010. View Article : Google Scholar : PubMed/NCBI
34	Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI
35	Chen JS, Wang Q, Fu XH, Huang XH, Chen XL, Cao LQ, Chen LZ, Tan HX, Li W, Bi J and Zhang LJ: Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: Association with MMP-9. Hepatol Res. 39:177–186. 2009. View Article : Google Scholar : PubMed/NCBI